期刊文献+

缬沙坦/硅胶固体分散体的制备和物理稳定性研究 被引量:1

Preparation of valsartan/silica gel solid dispersion and its physical stability
下载PDF
导出
摘要 目的制备缬沙坦(valsartan,VAL)/硅胶的固体分散体并进行性质研究。方法利用溶剂蒸发沉淀法制备VAL/硅胶固体分散体,通过溶出试验筛选确定制备方法,通过溶出试验、加速试验、差示扫描量热(DSC)和X-射线粉末衍射(XRD)等方法考察药物溶出行为、药物存在状态及物理稳定性。结果确定固体分散体的较优制备方法,载药量为23%~31%,30 min内药物的累计溶出超过90%,药物以非晶状态存在,加速试验证明VAL/硅胶固体分散体溶出和存在状态稳定。结论 VAL/硅胶固体分散体载药量较高,物理稳定性良好,明显提高了药物溶出速率。 Objective To prepare valsartan/silica gel solid dispersion and determine the basic characteristics of the solid dispersion. Methods The solid dispersions were prepared by solvent evaporation and precipitation method. A premium condition of preparing the solid dispersion was determined by screening dissolution of preparations. The dis- solution behaviors, drug state in the dispersion, and its stability were examined by dissolution test, acceleration test, differential scanning calorimetry and X-ray diffraction. Results The solid dispersion was prepared, the drug loading was about 23% -- 31%, the drug release within 30 min exceeded 90%, the dispersion was in amorphous state, and the stability of dissolution and state was proved by acceleration test. Conclusion The drug loading is high, valsartar/ silica gel solid dispersion is physically stable, and the dissolution is improved by solid dispersion.
出处 《中南药学》 CAS 2015年第10期1051-1054,共4页 Central South Pharmacy
关键词 缬沙坦 硅胶 固体分散体 溶出度 稳定性 valsartan silica gel solid dispersion dissolution stability
  • 相关文献

参考文献11

  • 1刘艳红.缬沙坦胶囊治疗糖尿病肾病效果观察[J].北方药学,2015,12(1):47-47. 被引量:1
  • 2Flesch G, Miiller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin 1I receptor ant-agonist, in man [J]. Eur J Clin Pharmacol, 1997, 52 ( 2 ) : 115-120.
  • 3Park Y J, Lee HK, Im YB, ct al. Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion [J]. Arch Pharm Res, 2010, 33 ( 8 ) : 1235-1240.
  • 4Yan YD, Sung JH, Kim KK, et al. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes [J]. Int J Pharm, 2012, 422 ( 1-2 ) : 202-210.
  • 5Dixit AR, Rajput S J, Patel SG. Preparation and bioavaila- bility assessment of SMEDDS containing valsartan [J]. AAPS PharmSciTech, 2010, 11 ( 1 ) : 314-321.
  • 6Zhang YZ, Wang JC, Bai XY, et al. Mesoporous silica na- nopartieles for increasing the oral bioavailability and permeati- on of poorly water soluble drugs [J]. Mol Pharm, 2012, 9( 3 ): 505-513.
  • 7Sun L, Wang Y, Jiang T, et al. Novel chitosan-functiona- lized spherical nanosilica matrix as an oral sustained drug de-livery system for poorly water-soluble drug carvedilol [J]. Acs Appl Mater Inter, 2013, 5 (1) : 103-113.
  • 8MeUaerts R, Jammaer JAG, Van Speybreck M, et al. Physi- cal state of poorly water soluble therapeutic molecules loaded into SBA-15 ordered mesoporous silica carriers: A case study with itraconazole and ibuprofen [J]. Langmuir, 2008, 24( 16 ): 8651-8659.
  • 9Heikkil~i T, Salonen J, Tuura J, et al. Evaluation of meso- porous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery [J]. Drug Deliv, 2007, 14 (6) : 337-347.
  • 10Xu W, Riikonen J, Lehto VP. Mesoporous systems for poorly soluble drugs [J]. Int JPharm, 2013, 453 ( 1 ) : 181-197.

二级参考文献2

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部